Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of this study was to evaluate the impact of in situ cross-linkers on the gelling and mucoadhesive properties of thiomers. Polycarbophil-cysteine conjugate (PCP-cys) was synthesized by covalent attachment of l-cysteine to polycarbophil via amide bond formation mediated by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC) and N-hydroxysuccinimide (NHS) whereas in situ cross-linkers (PAA-cys-
MNA
) were synthesized by the same bond formation between poly(acrylic acid) (PAA) of 2.1-, 6-, and 15kDa and 2-((2-amino-2-carboxyethyl)disulfanyl)nicotinic acid (cys-
MNA
) used as ligand. The in situ cross-linking properties were studied via rheological measurements of dynamic viscosity of mixtures of
PCP
-cys and PAA-cys-
MNA
with purified porcine intestinal mucus and via rotating cylinder method. The diffusion of polymers in purified porcine intestinal mucus was studied via rotating tube technique. The results showed that in situ cross-linkers (PAA 2.1-, 6-, 15kDa) increase the dynamic viscosity of
PCP
-cys/mucus mixtures by 5.1-, 5.6-, and 3.5-fold. Combinations of 10% of in situ cross-linkers PAA 2.1-, 6- or 15kDa and 90%
PCP
-cys increased the adhesion time 1.1-, 2.0- and 4.9-fold, respectively, compared to
PCP
-cys alone. Diffusion study showed that low molecular mass PAAs highly penetrate into the mucus gel layer due to their high polymer chain mobility compared to
PCP
-cys. The results provide evidence for the potential of in situ cross-linking agents as gelling and mucoadhesion enhancers.
...
PMID:Thiomers: Impact of in situ cross-linkers on mucoadhesive properties. 2854 80
